---
title: AI-READI Clinical Dataset
url: https://www.emergentmind.com/topics/ai-readi-clinical-dataset
type: topic
---

# AI-READI Clinical Dataset

The AI-READI Clinical Dataset is a large-scale, multimodal, and high-temporal-resolution resource enabling advanced research in glycemic forecasting, wearable sensor fusion, and cohort-based analysis for metabolic disease. Jointly collected by the AI-READI Consortium across three U.S. clinical sites, this flagship dataset comprises high-quality continuous glucose monitoring (CGM) data, physical activity measures, and extensive participant metadata spanning healthy, prediabetic, and type 2 diabetes (T2DM) populations. Its design, preprocessing, and benchmark applications provide a reproducible platform for artificial intelligence (AI) in digital health and clinical time-series modeling [2502.09919].

## 1. Dataset Composition and Cohort Structure

The AI-READI dataset’s analytic cohort contains 896 adult participants partitioned across four diagnostic bins:

| Cohort               | N  |
|----------------------|----|
| Healthy controls     | 323|
| Pre-diabetes         | 207|
| T2DM (oral agents)   | 258|
| T2DM (insulin users) | 108|

Initial enrollment comprised 1,067 subjects, with exclusion of participants exhibiting excessive missingness, ensuring analytic integrity. Recruitment produced a balanced representation by sex, race, and disease severity. The dataset is thus well-suited to comparative machine learning across metabolic phenotypes and therapeutic regimens [2502.09919].

## 2. Data Modalities, Temporal Resolution, and Preprocessing

Two primary modalities are included in the scope of published AI benchmark studies:

- **Continuous Glucose Monitor (CGM)**: Dexcom G6 devices sampled capillary-equivalent glucose values ($\mathbf{x}_g$) at uniform 5-minute intervals, providing dense coverage of diurnal glycemic variation.
- **Physical Activity Tracker**: Garmin Vivosmart 5 supplied both step count ($\mathbf{x}_{ws}$) and extracted walking intervals ($\mathbf{x}_{wi}$), with activity data characterized by irregular sampling due to device off-cycles or transient loss of contact.

Additional sensor channels—such as heart-rate variability, environmental factors, and stress indices—are present in the raw dataset but were not utilized in the initial AttenGluco benchmark. Data preprocessing employed the following sequence:

- **Imputation**: Occasional CGM gaps (5–10 minutes) were linearly interpolated; short duration activity dropout was imputed by forward-fill, while extended absences were coded as zero activity.
- **Normalization**: Z-score normalization ($z = (x - \mu)/\sigma$) was applied on a per-subject, per-channel basis.
  
This approach ensures regularity and comparability across subjects for transformer-based time-series modeling [2502.09919].

## 3. Metadata, Clinical Variables, and Curation Workflow

Each case includes structured metadata:

- Cohort assignment: healthy, pre-diabetes, T2DM on oral therapy, or T2DM on insulin.
- Demographics: age, sex, ethnicity, and cohort-specific identifiers.
- Device logs: CGM and wearable-derived signal completeness.
  
The curation process involved exclusion of subjects with excessive missing sensor data, outliers, or synchronization failures between modalities, resulting in a robust clinical time-series cohort [2502.09919].

## 4. Machine Learning Benchmarks and Evaluation Protocols

AttenGluco, a cross-modal transformer architecture, serves as the principal published benchmark exploiting the AI-READI dataset [2502.09919]. The evaluation framework encompasses several clinically relevant forecasting scenarios:

- **Sliding-window input**: 400 minutes (80 CGM steps) history per prediction.
- **Prediction horizons**: 5, 30, and 60 minutes into the future ($m \in \{1,6,12\}$).
- **Loss function**: Mean Squared Error (MSE).
- **Splits**:
  - *Isolated subject*: 85% train, 15% test, model re-initialized per subject.
  - *Cohort-wise fine-tuning*: Sequential training/fine-tuning across subjects within a cohort, evaluating adaptation.
  - *Continual learning*: Sequential fine-tuning across clinical cohorts without reinitialization, quantifying catastrophic forgetting.

### Primary Performance Metrics

| Metric               | Formula                                                                                                 |
|----------------------|--------------------------------------------------------------------------------------------------------|
| RMSE                 | $\sqrt{\tfrac{1}{N}\sum_{i=1}^N(\hat y_i - y_i)^2}$                                                    |
| MAE                  | $\tfrac{1}{N}\sum_{i=1}^N|\hat y_i - y_i|$                                                             |
| Pearson correlation  | $r=\frac{\sum_i(\hat y_i-\bar{\hat y})(y_i-\bar y)}{\sqrt{\sum_i(\hat y_i-\bar{\hat y})^2\sum_i(y_i-\bar y)^2}}$ |

AttenGluco exhibits consistent improvement over a multimodal 1D-CNN+LSTM baseline across all cohorts and tasks. For example, RMSE reductions of 9.1%–13.2% and MAE reductions of 9.7%–14.6% were observed cohort-wise, with substantive correlation increases (e.g., 0.59→0.67 in T2DM on insulin) [2502.09919].

## 5. Multimodal Fusion and Architectural Considerations

The dataset’s fusion potential arises from CGM’s dense regular sampling and activity’s sporadic/event-based reporting. AttenGluco addresses this through a dual-branch cross-attention mechanism, treating CGM as queries and walking activity as keys/values, enabling identification of temporal dependencies between physical activity and glycemic excursions. A multi-scale self-attention block captures both short- and long-term sequence motifs, supporting robust forecasting up to 60 minutes ahead with mitigated RMSE degradation compared to LSTM-based approaches [2502.09919].

*This suggests the AI-READI dataset is optimal for investigating novel transformer-based fusion architectures and temporal reasoning under irregular multimodal sampling.*

## 6. Clinical and Research Implications

The dataset’s detailed clinical stratification and high-fidelity time-series enable research into real-time glycemic control, closed-loop insulin delivery, and patient-specific lifestyle interventions. The observed performance of AttenGluco—with RMSE and MAE reductions of 10–15% compared to LSTM baselines—has implications for improving the safety and reliability of prediction-driven clinical decision support systems. Cohort-wise fine-tuning demonstrates adaptation capacity but highlights catastrophic forgetting when sequentially progressing through diverse metabolic populations, underlining future work in continual learning regularization [2502.09919].

A plausible implication is that advanced methods leveraging this dataset can support individualized therapeutic regimens and alert systems by accurately forecasting glucose perturbations in real-world, wearable-dominated contexts.

## 7. Access, Licensing, and Research Usage

The AI-READI Flagship Dataset, version 2.0.0, is publicly downloadable for bona fide research under open-access terms as detailed in benchmark publications [2502.09919]. It is intended as a reproducible foundation for the training, validation, and benchmarking of multimodal AI in digital health, with recommendations including subject-wise train/validation splits, careful cross-cohort evaluation, and modality-specific normalization. The dataset structure, quality controls, and accompanying analytic code establish a model for future clinical-grade, sensor-rich AI resources in endocrinology and beyond.

Source: https://www.emergentmind.com/topics/ai-readi-clinical-dataset